Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 42

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Design of ultrahigh-affinity and dual-specificity peptide antagonists of MDM2 and MDMX for P53 activation and tumor suppression

Li, Xiang, Gohain, Neelakshi, Chen, Si, Li, Yinghua, Zhao, Xiaoyuan, Li, Bo, Tolbert, William D., He, Wangxiao, Pazgier, Marzena, Hu, Honggang, Lu, Wuyuan · 2021 · Acta Pharmaceutica Sinica B

Abstract

Peptide inhibition of the interactions of the tumor suppressor protein P53 with its negative regulators MDM2 and MDMX activates P53 in vitro and in vivo, representing a viable therapeutic strategy for cancer treatment. Using phage display techniques, we previously identified a potent peptide activator of P53, termed PMI (TSFAEYWNLLSP), with binding affinities for both MDM2 and MDMX in the low nanomolar concentration range. Here we report an ultrahigh affinity, dual-specificity peptide antagonist of MDM2 and MDMX obtained through systematic mutational analysis and additivity-based molecular design. Functional assays of over 100 peptide analogs of PMI using surface plasmon resonance and fluorescence polarization techniques yielded a dodecameric peptide termed PMI-M3 (LTFLEYWAQLMQ) that bound to MDM2 and MDMX with Kd values in the low picomolar concentration range as verified by isothermal titration calorimetry. Co-crystal structures of MDM2 and of MDMX in complex with PMI-M3 were solved at 1.65 and 3.0 Å resolution, respectively. Similar to PMI, PMI-M3 occupied the P53-binding pocket of MDM2/MDMX, which was dominated energetically by intermolecular interactions involving Phe3, Tyr6, Trp7, and Leu10. Notable differences in binding between PMI-M3 and PMI were observed at other positions such as Leu4 and Met11 with MDM2, and Leu1 and Met11 with MDMX, collectively contributing to a significantly enhanced binding affinity of PMI-M3 for both proteins. By adding lysine residues to both ends of PMI and PMI-M3 to improve their cellular uptake, we obtained modified peptides termed PMI-2K (KTSFAEYWNLLSPK) and M3-2K (KLTFLEYWAQLMQK). Compared with PMI-2K, M3-2K exhibited significantly improved antitumor activities in vitro and in vivo in a P53-dependent manner. This super-strong peptide inhibitor of the P53-MDM2/MDMX interactions may become, in its own right, a powerful lead compound for anticancer drug development, and can aid molecular design of other classes of P53 activators as well for anticancer therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.apsb.2021.06.010

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 53

  1. Lane, 1992, Cancer. P53, guardian of the genome, Nature, 358, 15, 10.1038/358015a0 · DOI · Paper page
  2. Vogelstein, 2000, Surfing the P53 network, Nature, 408, 307, 10.1038/35042675 · DOI · Paper page
  3. Vousden, 2007, P53 in health and disease, Nat Rev Mol Cell Biol, 8, 275, 10.1038/nrm2147 · DOI · Paper page
  4. Haupt, 1997, MDM2 promotes the rapid degradation of P53, Nature, 387, 296, 10.1038/387296a0 · DOI · Paper page
  5. Xue, 2007, Senescence and tumour clearance is triggered by P53 restoration in murine liver carcinomas, Nature, 445, 656, 10.1038/nature05529 · DOI · Paper page
  6. Khoo, 2014, Drugging the P53 pathway: understanding the route to clinical efficacy, Nat Rev Drug Discov, 13, 217, 10.1038/nrd4236 · DOI · Paper page
  7. Zhang, 2014, Targeting P53‒MDM2‒MDMX loop for cancer therapy, Subcell Biochem, 85, 281, 10.1007/978-94-017-9211-0_16 · DOI
  8. Momand, 1992, The mdm-2 oncogene product forms a complex with the P53 protein and inhibits P53-mediated transactivation, Cell, 69, 1237, 10.1016/0092-8674(92)90644-R · DOI · Paper page
  9. Oliner, 1993, Oncoprotein MDM2 conceals the activation domain of tumour suppressor P53, Nature, 362, 857, 10.1038/362857a0 · DOI · Paper page
  10. Zhan, 2011, Peptide activators of the P53 tumor suppressor, Curr Pharm Des, 17, 603, 10.2174/138161211795222577 · DOI
  11. Fasan, 2004, Using a beta-hairpin to mimic an alpha-helix: cyclic peptidomimetic inhibitors of the P53‒HDM2 protein‒protein interaction, Angew Chem Int Ed Engl, 43, 2109, 10.1002/anie.200353242 · DOI · Paper page
  12. Harker, 2009, Beta-peptides with improved affinity for hDM2 and hDMX, Bioorg Med Chem, 17, 2038, 10.1016/j.bmc.2009.01.039 · DOI
  13. Li, 2009, Apamin as a template for structure-based rational design of potent peptide activators of P53, Angew Chem Int Ed Engl, 48, 8712, 10.1002/anie.200904550 · DOI
  14. Kritzer, 2006, Miniature protein inhibitors of the P53‒hDM2 interaction, Chembiochem, 7, 29, 10.1002/cbic.200500324 · DOI
  15. Hu, 2007, Efficient P53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX, Cancer Res, 67, 8810, 10.1158/0008-5472.CAN-07-1140 · DOI · Paper page
  16. Li, 2008, Turning a scorpion toxin into an antitumor miniprotein, J Am Chem Soc, 130, 13546, 10.1021/ja8042036 · DOI
  17. Vassilev, 2004, In vivo activation of the P53 pathway by small-molecule antagonists of MDM2, Science, 303, 844, 10.1126/science.1092472 · DOI · Paper page
  18. Li, 2010, Systematic mutational analysis of peptide inhibition of the P53-MDM2/MDMX interactions, J Mol Biol, 398, 200, 10.1016/j.jmb.2010.03.005 · DOI
  19. Schnolzer, 1992, In situ neutralization in Boc-chemistry solid phase peptide synthesis. Rapid, high yield assembly of difficult sequences, Int J Pept Protein Res, 40, 180, 10.1111/j.1399-3011.1992.tb00291.x · DOI · Paper page
  20. Dawson, 2000, Synthesis of native proteins by chemical ligation, Annu Rev Biochem, 69, 923, 10.1146/annurev.biochem.69.1.923 · DOI · Paper page
  21. Dawson, 1994, Synthesis of proteins by native chemical ligation, Science, 266, 776, 10.1126/science.7973629 · DOI · Paper page
  22. Pace, 1995, How to measure and predict the molar absorption coefficient of a protein, Protein Sci, 4, 2411, 10.1002/pro.5560041120 · DOI · Paper page
  23. Li, 2010, Limitations of peptide retro-inverso isomerization in molecular mimicry, J Biol Chem, 285, 19572, 10.1074/jbc.M110.116814 · DOI
  24. Zhan, 2012, Interrogation of MDM2 phosphorylation in P53 activation using native chemical ligation: the functional role of Ser17 phosphorylation in MDM2 reexamined, J Am Chem Soc, 134, 6855, 10.1021/ja301255n · DOI
  25. Zhan, 2012, An ultrahigh affinity d-peptide antagonist of MDM2, J Med Chem, 55, 6237, 10.1021/jm3005465 · DOI
  26. Otwinowski, 1997, Processing of X-ray diffraction data collected in oscillation mode, Methods Enzymol, 276, 307, 10.1016/S0076-6879(97)76066-X · DOI · Paper page
  27. Murshudov, 1997, Refinement of macromolecular structures by the maximum-likelihood method, Acta Crystallogr D Biol Crystallogr, 53, 240, 10.1107/S0907444996012255 · DOI · Paper page
  28. Li, 2019, Dithiocarbamate-inspired side chain stapling chemistry for peptide drug design, Chem Sci, 10, 1522, 10.1039/C8SC03275K · DOI
  29. Dill, 1997, Additivity principles in biochemistry, J Biol Chem, 272, 701, 10.1074/jbc.272.2.701 · DOI · Paper page
  30. Wells, 1990, Additivity of mutational effects in proteins, Biochemistry, 29, 8509, 10.1021/bi00489a001 · DOI · Paper page
  31. Li, 2020, Stapled helical peptides bearing different anchoring residues, Chem Rev, 120, 10079, 10.1021/acs.chemrev.0c00532 · DOI · Paper page
  32. Brown, 2013, Stapled peptides with improved potency and specificity that activate P53, ACS Chem Biol, 8, 506, 10.1021/cb3005148 · DOI · Paper page
  33. Chen, 2015, A stapled peptide antagonist of MDM2 carried by polymeric micelles sensitizes glioblastoma to temozolomide treatment through P53 activation, J Control Release, 218, 29, 10.1016/j.jconrel.2015.09.061 · DOI
  34. Zhao, 2014, Mirror image proteins, Curr Opin Chem Biol, 22, 56, 10.1016/j.cbpa.2014.09.019 · DOI
  35. Craik, 2013, The future of peptide-based drugs, Chem Biol Drug Des, 81, 136, 10.1111/cbdd.12055 · DOI · Paper page
  36. Bernal, 2007, Reactivation of the P53 tumor suppressor pathway by a stapled P53 peptide, J Am Chem Soc, 129, 2456, 10.1021/ja0693587 · DOI · Paper page
  37. Bautista, 2010, Bridged beta(3)-peptide inhibitors of P53‒hDM2 complexation: correlation between affinity and cell permeability, J Am Chem Soc, 132, 2904, 10.1021/ja910715u · DOI
  38. Zhang, 2011, Antiviral activity of alpha-helical stapled peptides designed from the HIV-1 capsid dimerization domain, Retrovirology, 8, 28, 10.1186/1742-4690-8-28 · DOI
  39. Takada, 2012, Targeted disruption of the BCL9/beta-catenin complex inhibits oncogenic Wnt signaling, Sci Transl Med, 4, 148ra117, 10.1126/scitranslmed.3003808 · DOI · Paper page
  40. Phillips, 2011, Design and structure of stapled peptides binding to estrogen receptors, J Am Chem Soc, 133, 9696, 10.1021/ja202946k · DOI · Paper page
  41. LaBelle, 2012, A stapled BIM peptide overcomes apoptotic resistance in hematologic cancers, J Clin Invest, 122, 2018, 10.1172/JCI46231 · DOI · Paper page
  42. Grossmann, 2012, Inhibition of oncogenic Wnt signaling through direct targeting of beta-catenin, Proc Natl Acad Sci U S A, 109, 17942, 10.1073/pnas.1208396109 · DOI · Paper page
  43. Bernal, 2011, A stapled P53 helix overcomes HDMX-mediated suppression of P53, Cancer Cell, 18, 411, 10.1016/j.ccr.2010.10.024 · DOI · Paper page
  44. Brown, 2013, Stapled peptides with improved potency and specificity that activate P53, ACS Chem Biol, 15, 506, 10.1021/cb3005148 · DOI · Paper page
  45. Chang, 2013, Stapled alpha-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for P53-dependent cancer therapy, Proc Natl Acad Sci U S A, 110, E3445, 10.1073/pnas.1303002110 · DOI · Paper page
  46. Philippe, 2016, Development of cell-penetrating peptide-based drug leads to inhibit MDMX: P53 and MDM2: P53 interactions, Biopolymers, 106, 853, 10.1002/bip.22893 · DOI
  47. Eckert, 1999, Inhibiting HIV-1 entry: discovery of d-peptide inhibitors that target the gp41 coiled-coil pocket, Cell, 99, 103, 10.1016/S0092-8674(00)80066-5 · DOI · Paper page
  48. Schumacher, 1996, Identification of d-peptide ligands through mirror-image phage display, Science, 271, 1854, 10.1126/science.271.5257.1854 · DOI · Paper page
  49. Liu, 2010, d-peptide inhibitors of the P53–MDM2 interaction for targeted molecular therapy of malignant neoplasms, Proc Natl Acad Sci U S A, 107, 14321, 10.1073/pnas.1008930107 · DOI · Paper page
  50. Zhan, 2015, Toxins and derivatives in molecular pharmaceutics: drug delivery and targeted therapy, Adv Drug Deliv Rev, 90, 101, 10.1016/j.addr.2015.04.025 · DOI
  51. Yan, 2021, A nano-predator of pathological MDMX construct by clearable supramolecular gold(I)-thiol-peptide complexes achieves safe and potent anti-tumor activity, Theranostics, 11, 6833, 10.7150/thno.59020 · DOI
  52. He, 2019, Self-assembly of therapeutic peptide into stimuli-responsive clustered nanohybrids for cancer-targeted therapy, Adv Funct Mater, 29, 1807736, 10.1002/adfm.201807736 · DOI
  53. Brunger, 1997, Free R value: cross-validation in crystallography, Methods Enzymol, 277, 366, 10.1016/S0076-6879(97)77021-6 · DOI · Paper page

Cited by

See all 42

Metadata

Authors
Li, X., Gohain, N., Chen, S., Li, Y., Zhao, X., Li, B., Tolbert, W. D., He, W., Pazgier, M., Hu, H., & Lu, W.
Venue
Acta Pharmaceutica Sinica B
Publisher
Elsevier BV
Published
2021-09
Volume
11
Issue
9
Pages
2655-2669
ISSN
2211-3835
Cited by
42
References
24
Language
en
Licence
Funders
  • National Institutes of Health
  • National Natural Science Foundation of China (21807112, 22077078, 82030062, 91849129)
  • U.S. Department of Energy
  • Shanghai Rising-Star Program
  • National Institute of General Medical Sciences
  • Office of Science
  • Biological and Environmental Research
  • Basic Energy Sciences (DE-AC02-76SF00515)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.